📣 VC round data is live. Check it out!

Roche Valuation Multiples

Discover revenue and EBITDA valuation multiples for Roche and similar public comparables like AbbVie, AstraZeneca, Novartis, Merck and more.

Roche Overview

About Roche

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.


Founded

1896

HQ

Switzerland

Employees

112.8K

Website

roche.com

Financials (LTM)

Revenue: $80B
EBITDA: $32B

EV

$346B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Roche Financials

Roche reported last 12-month revenue of $80B and EBITDA of $32B.

In the same LTM period, Roche generated $60B in gross profit, $32B in EBITDA, and $19B in net income.

Revenue (LTM)


Roche P&L

In the most recent fiscal year, Roche reported revenue of $82B and EBITDA of $31B.

Roche is profitable as of last fiscal year, with gross margin of 74%, EBITDA margin of 38%, and net margin of 22%.

See analyst estimates for Roche
LTMLast FY202320242025202620272028
Revenue$80B$82B$78B$80B$82B
Gross Profit$60B$60B$57B$59B$60B
Gross Margin74%74%73%74%74%
EBITDA$32B$31B$24B$21B$28B
EBITDA Margin40%38%31%27%34%
EBIT Margin35%35%25%22%29%
Net Profit$19B$18B$15B$11B$17B
Net Margin23%22%19%13%20%
Net Debt$34B

Financial data powered by Morningstar, Inc.

Roche Stock Performance

Roche has current market cap of $323B, and enterprise value of $346B.

Market Cap Evolution


Roche's stock price is $50.76.

Roche share price increased by 0.3% in the last 30 days, and by 24.8% in the last year.

Roche has an EPS (earnings per share) of $2.82.

See more trading valuation data for Roche
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$346B$323B0.0%0.3%-14.9%24.8%$2.82

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Roche Valuation Multiples

Roche trades at 4.3x EV/Revenue multiple, and 10.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Roche

EV / Revenue (LTM)


Roche Financial Valuation Multiples

As of May 10, 2026, Roche has market cap of $323B and EV of $346B.

Roche has a P/E ratio of 17.3x.

LTMLast FY202320242025202620272028
EV/Revenue4.3x4.2x4.4x4.3x4.2x
EV/EBITDA10.9x11.0x14.5x16.2x12.4x
EV/EBIT12.1x12.2x17.4x20.0x14.5x
EV/Gross Profit5.8x5.7x6.1x5.8x5.7x
P/E17.3x18.0x21.8x30.3x19.5x
EV/FCF18.4x18.7x23.5x17.8x20.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Roche Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Roche Margins & Growth Rates

Roche decreased revenue by 1% but EBITDA grew by 4% in the last fiscal year.

In the most recent fiscal year, Roche reported gross margin of 74%, EBITDA margin of 38%, and net margin of 22%.

See estimated margins and future growth rates for Roche

Roche Margins

Last FY202420252026202720282029
Gross Margin74%74%74%75%
EBITDA Margin38%27%34%40%
EBIT Margin35%22%29%35%
Net Margin22%13%20%25%
FCF Margin23%24%21%24%

Roche Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(1%)3%2%(1%)
Gross Profit Growth0%5%1%0%
EBITDA Growth4%(10%)31%16%
EBIT Growth1%(13%)38%20%
Net Profit Growth11%(28%)56%20%
FCF Growth4%32%(13%)14%

Data powered by FactSet, Inc. and Morningstar, Inc.

Roche Operational KPIs

Roche's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.

Roche's Rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Roche's Rule of X is 37% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Roche
LTMLast FY202320242025202620272028
Rule of 4041%39%
Bessemer Rule of X44%37%
Revenue per Employee$0.7M
Opex per Employee$0.3M
S&M Expenses to Revenue16%16%16%
G&A Expenses to Revenue1%24%25%24%24%
R&D Expenses to Revenue20%21%23%25%21%
Opex to Revenue45%47%52%45%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Roche Competitors

Roche competitors include AbbVie, AstraZeneca, Novartis, Merck, Siemens, Novo Nordisk, Amgen, Thermo Fisher Scientific, Gilead Sciences and Johnson & Johnson.

Most Roche public comparables operate across Biopharmaceuticals, Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
AbbVie6.8x6.6x17.3x15.4x
AstraZeneca5.3x15.8x
Novartis5.6x5.8x13.8x13.9x
Merck4.9x4.9x10.7x11.9x
Siemens2.9x2.9x14.6x15.9x
Novo Nordisk4.6x4.7x9.1x9.8x
Amgen6.1x6.0x13.3x13.3x
Thermo Fisher Scientific4.8x4.7x18.5x18.5x

This data is available for Pro users. Sign up to see all Roche competitors and their valuation data.

Start Free Trial

Roche M&A Activity

Roche has acquired 34 companies to date.

Last acquisition by Roche was on May 6th 2026. Roche acquired PathAI for $1B (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Roche

PathAI
89bio
Poseida Therapeutics
LumiraDx (PoC diagnostics platform unit)
Description
PathAI is a Boston-based provider of AI-powered pathology solutions founded in 2016. The platform automates tissue analysis for pharmaceutical research and clinical diagnostics, enabling precise cancer detection and drug development workflows. PathAI partners with biopharma leaders like Bristol Myers Squibb and integrates with major labs such as Quest Diagnostics across the United States and Europe. Its technology processes whole-slide images to quantify biomarkers, supporting over 40 clinical trials and routine pathology practices worldwide.
89bio is a San Francisco-headquartered biopharmaceutical company developing therapies for liver diseases and cardiometabolic conditions. Its lead candidate, pegozafermin, an FGF21 analog, advances in Phase 2b trials for NASH and severe hypertriglyceridemia. Founded in 2018, 89bio partners with Roche for global development rights outside Asia.
Poseida Therapeutics is a San Diego-headquartered clinical-stage biopharmaceutical company focused on engineered CAR-T therapies. It develops allogeneic and autologous T-cell products targeting hematologic cancers like multiple myeloma and solid tumors such as ovarian cancer. The pipeline includes P-BCMA-ALLO1 in Phase 1 trials and PT596 for broader oncology applications, leveraging proprietary CRISPR-based genome editing and non-viral DNA delivery. Poseida collaborates with Roche and Takeda on manufacturing and commercialization.
LumiraDx's Point of Care Diagnostics Platform operates a microfluidic testing system for rapid results in clinical settings. The UK-headquartered unit supports assays for cardiovascular markers, respiratory infections, and diabetes management using disposable cartridges compatible with portable readers. Deployed in hospitals across Europe and North America, the platform connects to electronic health records for seamless data integration.
HQ CountryUnited StatesUnited StatesUnited StatesUnited Kingdom
HQ City
Boston, MA
San Diego, CA
London
Deal Date6 May 202617 Sep 202526 Nov 202429 Dec 2023
Valuation$1B$2B$1B$295M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Roche acquisitions and their M&A valuation multiples.

Start Free Trial

Roche Investment Activity

Roche has invested in 3 companies to date.

Latest investment by Roche was on November 17th 2025. Roche invested in Freenome in their $75M Strategic investment round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Roche

Freenome
Freenome
Freenome
C4 Therapeutics
Description
Freenome is a South San Francisco-headquartered private biotechnology company specializing in early cancer detection via blood tests. It pioneers non-invasive screening using machine learning to analyze multiomics data for proactive management of cancers and other diseases. The approach aims to make advanced diagnostics accessible through innovative blood-based solutions.
Freenome is a South San Francisco-headquartered private biotechnology company specializing in early cancer detection via blood tests. It pioneers non-invasive screening using machine learning to analyze multiomics data for proactive management of cancers and other diseases. The approach aims to make advanced diagnostics accessible through innovative blood-based solutions.
Freenome is a South San Francisco-headquartered private biotechnology company specializing in early cancer detection via blood tests. It pioneers non-invasive screening using machine learning to analyze multiomics data for proactive management of cancers and other diseases. The approach aims to make advanced diagnostics accessible through innovative blood-based solutions.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
San Francisco, CA
San Francisco, CA
Deal Date17 Nov 202515 Feb 202411 Jan 20227 Jan 2016
RoundStrategic investmentUndisclosed stageStrategic investmentSeries A
Raised$75M$254M$290M$73M
InvestorsRocheRocheRocheCobro Ventures; Cormorant Asset Management; EG Capital Group; Novartis; Roche
Valuationundisclosed$1B$1Bundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Roche investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Roche

When was Roche founded?Roche was founded in 1896.
Where is Roche headquartered?Roche is headquartered in Switzerland.
How many employees does Roche have?As of today, Roche has over 112K employees.
Is Roche publicly listed?Yes, Roche is a public company listed on OTC Pink Sheets.
What is the stock symbol of Roche?Roche trades under RHHBY ticker.
When did Roche go public?Roche went public in 1994.
Who are competitors of Roche?Roche main competitors include AbbVie, AstraZeneca, Novartis, Merck, Siemens, Novo Nordisk, Amgen, Thermo Fisher Scientific, Gilead Sciences, Johnson & Johnson.
What is the current market cap of Roche?Roche's current market cap is $323B.
What is the current revenue of Roche?Roche's last 12 months revenue is $80B.
What is the current revenue growth of Roche?Roche revenue growth (NTM/LTM) is 2%.
What is the current EV/Revenue multiple of Roche?Current revenue multiple of Roche is 4.3x.
Is Roche profitable?Yes, Roche is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Roche?Roche's last 12 months EBITDA is $32B.
What is Roche's EBITDA margin?Roche's last 12 months EBITDA margin is 40%.
What is the current EV/EBITDA multiple of Roche?Current EBITDA multiple of Roche is 10.9x.
What is the current FCF of Roche?Roche's last 12 months FCF is $19B.
What is Roche's FCF margin?Roche's last 12 months FCF margin is 23%.
What is the current EV/FCF multiple of Roche?Current FCF multiple of Roche is 18.4x.
How many companies Roche has acquired to date?As of May 2026, Roche has acquired 34 companies.
What was the largest acquisition by Roche?$8B acquisition of InterMune on 24th August 2014 was the largest M&A Roche has done to date.
What companies Roche acquired?Roche acquired InterMune, Telavant, Spark Therapeutics, Carmot Therapeutics, 89bio, Flatiron Health, Foundation Medicine, GenMark Diagnostic, Ignyta, Promedior, and 24 other companies.
In how many companies Roche has invested to date?As of May 2026, Roche has invested in 3 companies.
What was the last Roche investment?On 17th November 2025 Roche invested in Freenome, participating in a $75M Strategic investment round.
In what companies Roche invested in?Roche invested in Freenome, Flatiron Health, and C4 Therapeutics.

See public comps similar to Roche

Lists including Roche

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial